Malignant Glioma

Oncology
12
Pipeline Programs
9
Companies
50
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
1
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 11 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Candel Therapeutics
3 programs
2
1
CAN-2409Phase 21 trial
AdV-tkPhase 11 trial
AdV-tkPhase 11 trial
Active Trials
NCT00634231CompletedEst. Jun 2021
NCT00751270CompletedEst. Jan 2011
NCT00589875CompletedEst. Aug 2016
E
EisaiChina - Liaoning
2 programs
2
Gliadel/Avastin/CPT-11Phase 21 trial
PalonosetronPhase 21 trial
Active Trials
NCT00735436Terminated18Est. Oct 2012
NCT00900757Completed57Est. Dec 2012
Celldex Therapeutics
1 program
1
CDX-110 with GM-CSFPhase 21 trial
Active Trials
NCT00458601Completed82Est. May 2016
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
1
CarboplatinPhase 21 trial
Active Trials
NCT00075387Unknown48Est. Apr 2024
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
EnzastaurinPhase 21 trial
Active Trials
NCT00190723Completed120Est. Dec 2006
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
vorinostatPhase 1/2Small Molecule5 trials
AP23573Phase 11 trial
Active Trials
NCT00087451Completed11Est. Nov 2005
NCT00419367No Longer Available
NCT03198559Terminated5Est. Apr 2019
+3 more trials
One Biosciences
One BiosciencesFrance - Paris
1 program
1
Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3LPhase 11 trial
Active Trials
NCT01811992CompletedEst. Jan 2021
Bristol Myers Squibb
1 program
1
nivolumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT02529072Completed6Est. Dec 2019
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Treatment Decision-making in Patients With Recurrent High-grade GliomaN/A1 trial
Active Trials
NCT04013828Completed29Est. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
EisaiPalonosetron
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
Merck & Co.vorinostat
EisaiGliadel/Avastin/CPT-11
Merck & Co.vorinostat

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 1,895 patients across 50 trials

NCT01720875Merck & Co.vorinostat

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Start: Aug 2013Est. completion: Aug 201816 patients
Phase 2Completed
NCT01738646Merck & Co.vorinostat

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

Start: Jan 2013Est. completion: Feb 201648 patients
Phase 2Completed
NCT01500538Merck & Co.vorinostat

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)

Start: Oct 2012Est. completion: May 20141 patients
Phase 2Terminated
NCT01617226Merck & Co.vorinostat

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS

Start: Sep 2012Est. completion: Dec 2020260 patients
Phase 2Completed
NCT01365065Merck & Co.vorinostat

Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy

Start: May 2011Est. completion: Jan 201820 patients
Phase 2Unknown
NCT01194427Merck & Co.vorinostat

A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Start: Mar 2011Est. completion: Nov 20112 patients
Phase 2Terminated
NCT01000155Merck & Co.vorinostat

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Start: Oct 2009Est. completion: Oct 20145 patients
Phase 2Terminated
NCT00948064Merck & Co.vorinostat

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Start: Sep 2009Est. completion: Aug 2017110 patients
Phase 2Completed
NCT00900757EisaiPalonosetron

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Start: Aug 2009Est. completion: Dec 201257 patients
Phase 2Completed
NCT00942266Merck & Co.vorinostat

Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment

Start: Jul 2009Est. completion: Dec 201158 patients
Phase 2Completed
NCT00875056Merck & Co.vorinostat

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Start: Apr 2009Est. completion: Feb 201956 patients
Phase 2Completed
NCT00810576Merck & Co.vorinostat

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Start: Jan 2009Est. completion: Apr 20101 patients
Phase 2Terminated
NCT00818649Merck & Co.vorinostat

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Start: Jan 2009Est. completion: May 201216 patients
Phase 2Terminated
NCT00735436EisaiGliadel/Avastin/CPT-11

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

Start: Dec 2008Est. completion: Oct 201218 patients
Phase 2Terminated
NCT00798720Merck & Co.vorinostat

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

Start: Dec 2008Est. completion: Oct 201218 patients
Phase 2Completed
NCT00720876Merck & Co.vorinostat

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Start: Jul 2008Est. completion: Jun 201730 patients
Phase 2Completed
NCT00656617Merck & Co.vorinostat

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Start: Apr 2008Est. completion: Feb 2014106 patients
Phase 2Completed
NCT00458601Celldex TherapeuticsCDX-110 with GM-CSF

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

Start: Aug 2007Est. completion: May 201682 patients
Phase 2Completed
NCT00486720Merck & Co.vorinostat

Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)

Start: Jun 2007Est. completion: Jul 200922 patients
Phase 2Terminated
NCT00589875Candel TherapeuticsCAN-2409

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

Start: Mar 2007Est. completion: Aug 2016
Phase 2Completed
NCT00365599Merck & Co.vorinostat

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Start: Feb 2006Est. completion: Aug 201243 patients
Phase 2Completed
NCT00907738Merck & Co.vorinostat

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Start: Aug 2005Est. completion: Jun 201027 patients
Phase 2Completed
NCT00097929Merck & Co.vorinostat

An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

Start: May 2005Est. completion: Jul 200618 patients
Phase 2Completed
NCT00091559Merck & Co.vorinostat

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Start: Feb 2005Est. completion: Mar 200674 patients
Phase 2Completed
NCT00126451Merck & Co.vorinostat

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Start: Dec 2004Est. completion: Oct 200516 patients
Phase 2Terminated
NCT00075387Knight TherapeuticsCarboplatin

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

Start: Mar 2003Est. completion: Apr 202448 patients
Phase 2Unknown
NCT00190723Eli Lilly and CompanyEnzastaurin

A Study of LY317615 in Patients With Brain Tumors

Start: Oct 2002Est. completion: Dec 2006120 patients
Phase 2Completed
NCT03198559Merck & Co.vorinostat

Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

Start: Aug 2017Est. completion: Apr 20195 patients
Phase 1/2Terminated
NCT01879085Merck & Co.vorinostat

Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Start: Sep 2013Est. completion: Apr 202137 patients
Phase 1/2Completed
NCT01534260Merck & Co.vorinostat

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

Start: Feb 2012Est. completion: Feb 201737 patients
Phase 1/2Completed
NCT01502085Merck & Co.vorinostat

Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens

Start: Dec 2011Est. completion: May 201625 patients
Phase 1/2Completed
NCT01266031Merck & Co.vorinostat

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Start: Jul 2011Est. completion: Jan 201796 patients
Phase 1/2Completed
NCT01110876Merck & Co.vorinostat

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Start: Jun 2011Est. completion: Jul 201421 patients
Phase 1/2Terminated
NCT01294670Merck & Co.vorinostat

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Start: Feb 2011Est. completion: Dec 202027 patients
Phase 1/2Completed
NCT01120834Merck & Co.vorinostat

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Start: Sep 2010Est. completion: Oct 201617 patients
Phase 1/2Completed
NCT01027676Merck & Co.vorinostat

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

Start: Jun 2010Est. completion: Mar 201450 patients
Phase 1/2Unknown
NCT00976183Merck & Co.vorinostat

Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Start: Oct 2009Est. completion: Oct 201218 patients
Phase 1/2Terminated
NCT00972842Merck & Co.vorinostat

Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

Start: Sep 2009Est. completion: Jul 201220 patients
Phase 1/2Terminated
NCT00948688Merck & Co.vorinostat

Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas

Start: Aug 2009Est. completion: Nov 201310 patients
Phase 1/2Terminated
NCT00910000Merck & Co.vorinostat

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Start: Jun 2009Est. completion: Oct 201515 patients
Phase 1/2Terminated
NCT00831493Merck & Co.vorinostat

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

Start: May 2009Est. completion: Oct 20103 patients
Phase 1/2Terminated
NCT00702962Merck & Co.vorinostat

Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

Start: Sep 2008Est. completion: Jul 20128 patients
Phase 1/2Terminated
NCT00503971Merck & Co.vorinostat

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Start: May 2008Est. completion: Dec 201133 patients
Phase 1/2Terminated
NCT00574587Merck & Co.vorinostat

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Start: Dec 2007Est. completion: May 201455 patients
Phase 1/2Completed
NCT00555399Merck & Co.vorinostat

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Start: Nov 2007Est. completion: Jan 202055 patients
Phase 1/2Terminated
NCT00416130Merck & Co.vorinostat

Clinical Trial of SAHA in Patients With Breast Cancer

Start: Jan 2007Est. completion: Jan 201549 patients
Phase 1/2Unknown
NCT00251589Merck & Co.vorinostat

A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

Start: Jan 2006Est. completion: Oct 200723 patients
Phase 1/2Terminated
NCT02529072Bristol Myers Squibbnivolumab

Nivolumab With DC Vaccines for Recurrent Brain Tumors

Start: Jan 2016Est. completion: Dec 20196 patients
Phase 1Completed
NCT01811992One BiosciencesDose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L

Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma

Start: Apr 2014Est. completion: Jan 2021
Phase 1Completed
NCT01174199Merck & Co.vorinostat

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Start: Feb 2012Est. completion: Aug 201613 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)